stockrowIntegra LifeSciences Holdings Corporation
IART Healthcare Medical Devices
Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024.
- Revenue
- +2.27%
- EPS
- +371.4%
- Free cash flow
- +232.9%
- Total debt
- −0.79%
Quarter to September 2026, against a year earlier
Follow IART
Alert me
Integra LifeSciences Holdings Corporation (IART) EV/Sales
As of 5 November 2026, Integra LifeSciences Holdings Corporation (IART) trades at a EV/Sales of 1.6×. Over the past ten years it has ranged from 1.4× (March 2026) to 5.6× (April 2021); the current reading is higher than 6% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.5× | (23.88%) |
| FY2024 | 2.0× | (34.19%) |
| FY2023 | 3.1× | (15.30%) |
| FY2022 | 3.6× | (17.13%) |
| FY2021 | 4.4× | (8.67%) |
| FY2020 | 4.8× | 17.70% |
| FY2019 | 4.1× | 20.99% |
| FY2018 | 3.4× | (23.77%) |
| FY2017 | 4.4× | 16.78% |
| FY2016 | 3.8× | 11.16% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.7× | (7.66%) |
| Jun 2026 | 1.8× | 27.42% |
| Mar 2026 | 1.4× | (5.80%) |
| Dec 2025 | 1.5× | (21.30%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AHCO AdaptHealth Corp. compare | 0.8× |
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.2× |
| IART Integra LifeSciences Holdings Corporation | 1.6× |
| ATEC Alphatec Holdings, Inc. compare | 2.0× |
| PRCT PROCEPT BioRobotics Corporation compare | 2.8× |
| AORT Artivion, Inc. compare | 3.2× |
| SIBN SiBone compare | 4.4× |
| CBLL CeriBell, Inc. compare | 8.3× |
| IRMD iRadimed Corporation compare | 11.4× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)